Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03207152
Other study ID # Pro00082500
Secondary ID
Status Enrolling by invitation
Phase Phase 1
First received
Last updated
Start date September 11, 2017
Est. completion date February 28, 2019

Study information

Verified date July 2018
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to test the hypothesis that gene transcriptional changes occur within 24 hours of virus exposure in the blood and nasal mucosa, and to identify early biomarker signatures that are predictive of higher viral shedding at the peak of disease


Description:

This study will systematically investigate the early pre-symptomatic period following exposure to influenza in humans. The data obtained will be essential for further understanding of the natural history of human antiviral responses, and will allow us to identify a panel of biomarkers that can predict which individuals will go on to more severe symptoms and higher viral shedding, so that treatments and other interventions can be made at an early stage.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 50
Est. completion date February 28, 2019
Est. primary completion date May 8, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Healthy persons aged 18 to 55 years, able to give informed consent

Exclusion Criteria:

- Chronic respiratory disease (asthma, chronic obstructive pulmonary disease, rhinitis, sinusitis) in adulthood

- Inhaled bronchodilator or steroid use within the last 12 months

- Use of any medication or other product (prescription or over-the-counter) for symptoms of rhinitis or nasal congestion within the last 6 months

- Acute upper respiratory infection or sinusitis in the past 6 weeks

- Smoking in the past 6 months OR >5 pack-year lifetime history

- Subjects with allergic symptoms present at baseline

- Clinically relevant abnormality on chest X-ray

- Those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 3 years, the elderly (>65 years), immunosuppressed persons, or those with chronic respiratory disease

- Subjects with known or suspected immune deficiency

- Receipt of systemic glucocorticoids (in a dose = 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months prior to challenge

- Known immunoglobulin A deficiency, immotile cilia syndrome, or Kartagener's syndrome

- History of frequent nose bleeds

- Any significant medical condition or prescribed drug deemed by the study doctor to make the participant unsuitable for the study

- Pregnant or breastfeeding women

- Positive urine drug screen

- Detectable baseline haemagglutination inhibition titres against influenza challenge strains

- History of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine, or with life-threatening reactions to previous influenza vaccinations

All women of childbearing age will have a pregnancy test performed prior to virus inoculation to exclude pregnancy and be required to use contraception throughout the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Influenza A/California/04/09
Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops

Locations

Country Name City State
United Kingdom Imperial College London London

Sponsors (3)

Lead Sponsor Collaborator
Duke University Imperial College of London, United States Department of Defense

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Viral load Nasal wash viral load by quantitative polymerase chain reaction (qPCR) 28 days
Secondary Symptoms Self-reported upper and lower respiratory and systemic symptoms by diary card 28 days
Secondary Differentially expressed genes in blood Differentially expressed genes analysed by RNA sequencing of whole blood 9 months
Secondary Differentially expressed genes in nasal curettage Differentially expressed genes analysed by RNA sequencing of nasal curettage samples 9 months
Secondary Metabolomics in serum Differentially expressed metabolites in serum by mass spectrometry 9 months
See also
  Status Clinical Trial Phase
Completed NCT03999554 - Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines Phase 1
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Completed NCT02487173 - Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B N/A
Completed NCT01701752 - Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults Phase 1
Terminated NCT05567783 - A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A Phase 2
Not yet recruiting NCT00987012 - The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients N/A
Not yet recruiting NCT05928507 - FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
Completed NCT03651544 - The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac Phase 1
Completed NCT02623322 - A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults Phase 2
Completed NCT03196661 - Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population Phase 1
Recruiting NCT06160531 - Influenza Viral Challenge Study of CC-42344 in Healthy Participants Phase 2
Recruiting NCT06191393 - SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings N/A
Completed NCT06127108 - Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel N/A
Completed NCT05163730 - Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel N/A
Not yet recruiting NCT06392451 - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia N/A
Recruiting NCT04896853 - Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® Phase 1
Not yet recruiting NCT05787444 - Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
Completed NCT05354115 - Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel. N/A
Completed NCT02014870 - Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers Phase 1
Completed NCT05897515 - LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia N/A